a public good project by the
Synthesis
Company
of California

© 2026

Cheng Cheng | doi.page

0 works0 citations0 h-index

Cheng Cheng

University of Science and Technology of China(CN)Sir Run Run Shaw Hospital(CN)First Affiliated Hospital Zhejiang University(CN)

Publications by Year

Research Areas

Acute Lymphoblastic Leukemia research, Epigenetics and DNA Methylation, Cancer Genomics and Diagnostics, Childhood Cancer Survivors' Quality of Life, Genomics and Rare Diseases

Most-Cited Works

→ The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias(2015)490 cited
→ A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma(2024)20 cited
→ Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management(2023)13 cited
→ Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors(2024)13 cited
→ Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk(2024)12 cited
→ VCP downstream metabolite glycerol-3-phosphate (G3P) inhibits CD8+T cells function in the HCC microenvironment(2025)8 cited

→ Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer(2025)

3 cited

→ Bootstrap Evaluation of Association Matrices (BEAM) for Integrating Multiple Omics Profiles with Multiple Outcomes(2024)1 cited

→ Supplementary Data- Tables TS1-6 from Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management(2023)

→ Supplementary Table S21 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk(2024)